在N.H.S.S.中做出决策

Same author

Can pain flares in knee osteoarthritis be predicted?

Scandinavian journal of rheumatology·2021

Same author

Cost-effectiveness of duloxetine for knee OA subjects: the role of pain severity.

Osteoarthritis and cartilage·2020

Same author

Association of weather factors with the risk of pain exacerbations in people with hip osteoarthritis.

Scandinavian journal of rheumatology·2020

Same author

Is the Patient Activation Measure a valid measure of osteoarthritis self-management attitudes and capabilities? Results of a Rasch analysis.

Health and quality of life outcomes·2020

Same author

Association of baseline and change in tibial and femoral cartilage thickness and development of widespread full-thickness cartilage loss in knee osteoarthritis - data from the Osteoarthritis Initiative.

Osteoarthritis and cartilage·2020

Same author

A consensus-based framework for conducting and reporting osteoarthritis phenotype research.

Arthritis research & therapy·2020

Same journal

Assisted dying and the silencing of medicine's next generation.

Lancet (London, England)·2026

Same journal

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Lancet (London, England)·2026

Same journal

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

Lancet (London, England)·2026

Same journal

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Lancet (London, England)·2026

Same journal

Research priorities for characterising Bundibugyo virus.

Lancet (London, England)·2026

Same journal

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

Lancet (London, England)·2026

相关实验视频

在N.H.S.S.中做出决策

相关概念视频

Can pain flares in knee osteoarthritis be predicted?

Cost-effectiveness of duloxetine for knee OA subjects: the role of pain severity.

Association of weather factors with the risk of pain exacerbations in people with hip osteoarthritis.

Is the Patient Activation Measure a valid measure of osteoarthritis self-management attitudes and capabilities? Results of a Rasch analysis.

Association of baseline and change in tibial and femoral cartilage thickness and development of widespread full-thickness cartilage loss in knee osteoarthritis - data from the Osteoarthritis Initiative.

A consensus-based framework for conducting and reporting osteoarthritis phenotype research.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.

相关实验视频

在N.H.S.S.中做出决策

相关概念视频

相关文章

Can pain flares in knee osteoarthritis be predicted?

Cost-effectiveness of duloxetine for knee OA subjects: the role of pain severity.

Association of weather factors with the risk of pain exacerbations in people with hip osteoarthritis.

Is the Patient Activation Measure a valid measure of osteoarthritis self-management attitudes and capabilities? Results of a Rasch analysis.

Association of baseline and change in tibial and femoral cartilage thickness and development of widespread full-thickness cartilage loss in knee osteoarthritis - data from the Osteoarthritis Initiative.

A consensus-based framework for conducting and reporting osteoarthritis phenotype research.

Assisted dying and the silencing of medicine's next generation.

Linguistic pragmatism: a woman with progressive abdominal pain in Thailand.

Medical compartmentalisation: a patient with chromosome 22q11.2 deletion syndrome in Japan.

[<sup>177</sup>Lu]Lu-edotreotide versus everolimus for gastroenteropancreatic neuroendocrine tumours (COMPETE): a phase 3, multicentre, randomised, open-label, superiority trial.

Research priorities for characterising Bundibugyo virus.

Rethinking treatment sequence in advanced gastroenteropancreatic neuroendocrine tumours.